炎症性肠病缓解期患者由静脉英夫利西单抗转换为皮下英夫利西单抗1年后的持续性与安全性
这项前瞻性多中心法国队列研究纳入426例至少6个月无激素临床缓解的炎症性肠病患者,在由静脉英夫利西单抗转换为皮下英夫利西单抗后第48周评估持续性、有效性和耐受性。第48周皮下英夫利西单抗持续性为95.4%(95%CI 93.3%-97.5%),86.9%患者维持无激素临床缓解,英夫利西单抗平均谷浓度由纳入时8.0 μg/mL升至第48周18.0 μg/mL(P < .0001)。
要点
- 第48周皮下英夫利西单抗持续性为95.4%(95%CI 93.3%-97.5%)。
- 第48周86.9%患者维持无激素临床缓解。
- 英夫利西单抗平均水平由纳入时8.0 μg/mL升至第48周18.0 μg/mL(P < .0001)。
核心结论
- 在这项大型多中心前瞻性队列中,由静脉英夫利西单抗转换的缓解期炎症性肠病患者1年皮下英夫利西单抗持续性超过95%,证实皮下英夫利西单抗具有良好的有效性和耐受性。
研究设计与样本
- 前瞻性多中心法国队列研究,纳入至少6个月无激素临床缓解且正在使用静脉英夫利西单抗的炎症性肠病患者,在转换为皮下英夫利西单抗时入组。
- 共纳入426例患者,其中克罗恩病72.4%、溃疡性结肠炎27.5%,女性45.1%,中位年龄37岁(四分位距29-50岁),克罗恩病中位病程12年、溃疡性结肠炎中位病程13年。
- 基线时56%患者使用静脉英夫利西单抗标准剂量(5 mg/kg 每8周),16%接受免疫调节剂联合治疗。
- 在纳入时及第12、24、48周进行评估,主要终点为第48周皮下英夫利西单抗持续性。
主要发现
- 第48周皮下英夫利西单抗持续性为95.4%(95%CI 93.3%-97.5%),86.9%患者处于无激素临床缓解。
- 英夫利西单抗平均水平在纳入时为8.0 μg/mL,第48周为18.0 μg/mL(P < .0001)。
- 19例(4.5%)患者停止皮下英夫利西单抗,其中6例(1.4%)转回静脉英夫利西单抗。
- 42.4%患者报告222例不良事件,12例导致治疗中断,包括6例(1.4%)严重不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Real-life data regarding inflammatory bowel disease (IBD) evolution after switch from intravenous infliximab (IV-IFX) to subcutaneous infliximab (SC-IFX) is necessary. The aim of this prospective multicenter cohort study was to describe the persistence, effectiveness and tolerance of SC-IFX after switch from IV-IFX. METHODS: IBD patients in steroid-free clinical remission for at least 6 months on IV-IFX were enrolled in a prospective national French cohort when they switched to SC-IFX. Patients were assessed at inclusion and at weeks 12, 24, and 48. The primary endpoint was the persistence of SC-IFX at week 48. Secondary endpoints comprised steroid-free clinical remission at week 48, IV-IFX switch-back rate, and evolution of infliximab levels during the study period. RESULTS: Among the 426 patients included (72.4% with Crohn's disease , 27.5% with ulcerative colitis; 45.1% female; median age 37 [interquartile range, 29-50] years; median disease duration of 12 years in Crohn's disease, 13 years in ulcerative colitis), 56% were on IV-IFX standard dosing (5 mg/kg 8-weekly) and 16% received combination therapy with an immunomodulator drug at baseline. At week 48, SC-IFX persistence was 95.4% (95% confidence interval, 93.3%-97.5%) and 86.9% of patients were on steroid-free clinical remission. Mean infliximab levels were 8.0 μg/mL at inclusion and 18.0 μg/mL at week 48 (P < .0001). Among the 19 (4.5%) patients who stopped SC-IFX, 6 (1.4%) switched back to IV-IFX. There were 222 adverse events reported in 42.4% of patients, and 12 led to treatment discontinuation, including 6 (1.4%) severe adverse events. CONCLUSIONS: In this large multicenter prospective cohort, persistence at 1 year of SC-IFX was more than 95% of IBD patients switched in remission from IV-IFX, confirming excellent effectiveness and tolerance of SC-IFX.
引用
- Mathieu N, Hupé M, Heluwaert F, et al. PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission. Clin Gastroenterol Hepatol. 2025. PMID: 40398832. doi:10.1016/j.cgh.2025.04.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。